Bridge Biotherapeutics enrols all subjects in idiopathic pulmonary fibrosis drug trial

Bridge Biotherapeutics enrols all subjects in idiopathic pulmonary fibrosis drug trial

Bridge Biotherapeutics has completed enrollment for a Phase II trial of BBT-877, an autotoxin inhibitor for idiopathic pulmonary fibrosis. The study aims to evaluate efficacy, safety, and tolerability, with results expected in the first half of next year.

Read More

Did you find this insightful?